Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 14/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 14/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 14/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 14/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 14/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 12/20 | 1.00 |
| ▸ | GABRP | O00591 | 7/20 | 1.00 |
| ▸ | GABRD | O14764 | 7/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 7/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 7/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 7/20 | 1.00 |
| ▸ | GABRE | P78334 | 7/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 7/20 | 1.00 |
| ▸ | GABRG1 | Q8N1C3 | 7/20 | 1.00 |
| ▸ | GABRG3 | Q99928 | 7/20 | 1.00 |
| ▸ | GABRQ | Q9UN88 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30218831 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL31623721 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Hydrochloric Acid SCHEMBL30416830 | 0.99 | GABRA1 (0.98) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Hydrochloric Acid SCHEMBL19695338 | 0.99 | GABRA1 (0.98) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL10416974 | 0.93 | GABRA1 (0.86) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9840031 | 0.93 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL31623771 | 0.92 | GABRA1 (0.85) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL31623728 | 0.91 | GABRA1 (0.84) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL31623784 | 0.91 | GABRA1 (0.83) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9426110 | 0.91 | GABRA1 (0.83) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-20030176456-A1 | Methods for reducing alcohol cravings in chronic alcoholics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-09-18 | — | — | US | disclosed |
| US-5700808-A | TREATING SLEEP DISTURBANCE, EPILEPSY | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-12-23 | — | — | US | disclosed |
| US-5414002-A | Anxiolytic agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-05-09 | — | — | US | disclosed |
| EP-0520987-A1 | METHOD OF SUPPRESSING APPETITE BY ADMINISTRATION OF TETRAHYDRO-$g(b)-CARBOLINE DERIVATIVES | NEUREX CORPORATION (US) | 1993-01-07 | — | — | EP | disclosed |
| US-5169852-A | Anorexigenic agents | NEUREX CORPORATION (US) | 1992-12-08 | — | — | US | disclosed |
| US-4978669-A | ALTERING MACRONUTRIENT PREFERENCE | NEUREX CORPORATION (US) | 1990-12-18 | — | — | US | disclosed |
| WO-1990014827-A1 | METHOD OF SUPPRESSING APPETITE BY ADMINISTRATION OF TETRAHYDRO-β-CARBOLINE DERIVATIVES | NEUREX CORPORATION (US) | 1990-12-13 | — | — | WO | disclosed |
| EP-0054507-B1 | 3-SUBSTITUTED BETA-CARBOLINES, PROCESS FOR THEIR PRODUCTION AND COMPOSITIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-02-17 | — | — | EP | disclosed |
| US-4596808-A | Nervous system disorders | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-06-24 | — | — | US | disclosed |
| US-4435403-A | TRANQUILIZERS | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-03-06 | — | — | US | disclosed |
| EP-0054507-A2 | 3-Substituted beta-carbolines, process for their production and compositions containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | GABRB2, GABRA4, GABRB1 | GABRA1 5/4885GABRG2 12/4885GABRB3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.